Core Viewpoint - Beta Bionics, Inc. has faced significant stock declines following disappointing preliminary fourth-quarter 2025 performance metrics, raising concerns among investors regarding the company's growth prospects [4][5]. Group 1: Company Performance - On January 9, 2026, Beta Bionics reported lower-than-expected new patient starts for its iLet automated insulin delivery system, which contributed to investor concerns about near-term adoption trends and revenue growth [5]. - Following the announcement, Beta Bionics' stock price dropped approximately $11.85, or 37.04%, closing at $20.14 on the same day [5]. Group 2: Legal Investigation - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics for investors who suffered significant losses due to the stock's decline [2][4]. - The law firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for misleading statements made during the Class Period from May 9, 2024, to May 8, 2025, which allegedly resulted in investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Iovance made false or misleading statements regarding the initiation of patient treatments at newly authorized treatment centers (ATCs) [3]. - It is alleged that Iovance's sales team and ATCs faced challenges in effectively identifying and selecting patients, leading to higher patient drop-off rates [3]. - These operational issues reportedly resulted in increased costs and reduced revenue, as ATCs could not keep pace with product manufacturing [3]. - The lawsuit contends that the positive statements made by Iovance regarding its business and outlook were materially misleading or lacked a reasonable basis [3]. Group 2: Investor Actions - Investors who purchased Iovance securities during the Class Period have until July 14, 2025, to file a lead plaintiff motion [1]. - The Portnoy Law Firm is offering complimentary case evaluations to discuss options for recovering losses [2][4].